|
|
||||||||
Technical Developments |
1 From the Department of Radiology (J.P.D., D.M.P, L.H.S., D.B.), Weill Medical College of Cornell University, 1300 York Ave, Box 234, New York, NY 10021-4885; Departments of Radiology (D.M.P., L.H.S., J.A.K., D.B.), Surgery (J.H.H.), Pediatrics (P.A.M., R.G.), Pathology (A.G.H.), Biostatistics (H.T.T.), Medical Physics (J.A.K., D.B.), and Medicine (J.A.K.), Memorial Sloan-Kettering Cancer Center, New York, NY; and Institute of Neurology, University College London, England (P.S.T.). Received October 9, 2001; revision requested January 2, 2002; final revision received October 16; accepted November 6. Supported in part by National Institutes of Health grants R01HL50139, CA05826-038A1, and RO1CA62556. Address correspondence to J.P.D. (e-mail: jpd2001@med.cornell.edu).
Dynamic contrast materialenhanced magnetic resonance (MR) images of primary osteogenic sarcoma (n = 19) and Ewing sarcoma (n = 10) were reviewed in 29 patients undergoing induction chemotherapy before surgery. Histogram distributions containing the initial slope and pharmacokinetic model parameters from individual voxels within each tumor were fitted for each patient. The histogram analysis of initial slope from the tumor correlated well with percentage necrosis as determined at pathologic examination (r = 0.60, P < .001), as did a two-compartment pharmacokinetic model (r = 0.64, P < .001). Both methods predicted tumors with clinically important degrees of necrosis (ie, ≥90%) in a large majority of cases. The ability to determine response to induction chemotherapy by means of noninvasive monitoring of necrotic fraction with perfusion MR imaging methods may provide useful prognostic information and help surgical planning.
© RSNA, 2003
Index terms: Bone neoplasms, MR, 41.12143, 44.12143, 45.12143 Chemotherapy, 41.3221, 41.3281, 44.3221, 44.3281, 45.3221, 45.3281 Ewing sarcoma, 41.3281, 44.3281, 45.3281 Osteosarcoma, 41.3221, 44.3221, 45.3221
This article has been cited by other articles:
![]() |
M. S. Kim, S.-Y. Lee, W. H. Cho, W. S. Song, J.-S. Koh, J. A. Lee, J. Y. Yoo, and D.-G. Jeon Tumor Necrosis Rate Adjusted by Tumor Volume Change Is a Better Predictor of Survival of Localized Osteosarcoma Patients Ann. Surg. Oncol., March 1, 2008; 15(3): 906 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol. Cancer Ther., August 1, 2006; 5(8): 1950 - 1957. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Thoeny, F. De Keyzer, V. Vandecaveye, F. Chen, X. Sun, H. Bosmans, R. Hermans, E. K. Verbeken, C. Boesch, G. Marchal, et al. Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging Radiology, November 1, 2005; 237(2): 492 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van Vliet, C. F. van Dijke, P. A. Wielopolski, T. L. M. ten Hagen, J. F. Veenland, A. Preda, A. J. Loeve, A. M. M. Eggermont, and G. P. Krestin MR Angiography of Tumor-related Vasculature: From the Clinic to the Micro-environment RadioGraphics, October 1, 2005; 25(suppl_1): S85 - S97. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |